145 related articles for article (PubMed ID: 24013519)
1. A mixed-type autoimmune hemolytic anemia with immune thrombocytopenia related with myositis and post-transplantation lymphoproliferative disorder.
Ogura M; Ichikawa M; Masuda A; Kandabashi K; Nannya Y; Kurokawa M
Ann Hematol; 2014 May; 93(5):869-71. PubMed ID: 24013519
[No Abstract] [Full Text] [Related]
2. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant.
Thoma MD; Huneke TJ; DeCook LJ; Johnson ND; Wiegand RA; Litzow MR; Hogan WJ; Porrata LF; Holtan SG
Biol Blood Marrow Transplant; 2012 Apr; 18(4):600-7. PubMed ID: 21843495
[TBL] [Abstract][Full Text] [Related]
3. Immune-Mediated Cytopenias After Hematopoietic Cell Transplantation: Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment Strategies.
Michniacki TF; Ebens CL; Choi SW
Curr Oncol Rep; 2019 Aug; 21(10):87. PubMed ID: 31414187
[TBL] [Abstract][Full Text] [Related]
4. Is graft-versus-leukemia more effective using reduced-intensity conditioning compared with myeloablative conditioning?
Ringdén O; Sadeghi B
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1615-7. PubMed ID: 23022465
[No Abstract] [Full Text] [Related]
5. Marked eosinophilia with abnormal basophilic granules in acute graft-versus-host disease post-allogeneic haemopoietic stem cell transplant for acute myeloid leukaemia without CBFB-MYH11 mutation.
Chew E; Mason KD; Juneja S
Eur J Haematol; 2013 Feb; 90(2):175-6. PubMed ID: 23106290
[No Abstract] [Full Text] [Related]
6. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up.
Shimoni A; Hardan I; Shem-Tov N; Yerushalmi R; Nagler A
Leukemia; 2010 May; 24(5):1050-2. PubMed ID: 20147978
[No Abstract] [Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): how can we improve outcomes in the near future?
Phillips GL
Leuk Res; 2012 Dec; 36(12):1490-5. PubMed ID: 22954609
[TBL] [Abstract][Full Text] [Related]
8. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
9. Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia.
Cho BS; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1552-63. PubMed ID: 22516055
[TBL] [Abstract][Full Text] [Related]
10. Serial measurement of WT1 expression and decrement ratio until hematopoietic cell transplantation as a marker of residual disease in patients with cytogenetically normal acute myelogenous leukemia.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):958-66. PubMed ID: 23542687
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
12. Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk.
Dahl D; Hahn A; Koenecke C; Heuft HG; Dammann E; Stadler M; Buchholz S; Krauter J; Eder M; Sykora KW; Klein C; Ganser A; Sauer M
Transfusion; 2010 Mar; 50(3):649-55. PubMed ID: 19929861
[TBL] [Abstract][Full Text] [Related]
13. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.
Craddock CF
Bone Marrow Transplant; 2008 Mar; 41(5):415-23. PubMed ID: 18209726
[TBL] [Abstract][Full Text] [Related]
14. Post-allogeneic transplant Evans syndrome successfully treated with daratumumab.
Blennerhassett R; Sudini L; Gottlieb D; Bhattacharyya A
Br J Haematol; 2019 Oct; 187(2):e48-e51. PubMed ID: 31441030
[No Abstract] [Full Text] [Related]
15. NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia.
Terwey TH; Vega-Ruiz A; Hemmati PG; Martus P; Dietz E; le Coutre P; Massenkeil G; Dörken B; Arnold R
Leukemia; 2012 Mar; 26(3):536-42. PubMed ID: 21869841
[No Abstract] [Full Text] [Related]
16. [Autopsy case of SLE complicated by thrombocytopenia, hemolytic anemia, multiple myositis and lung aspergillus].
Nagano T; Higo S; Yamaguchi A; Tanabe J
Naika; 1968 Sep; 22(3):784-8. PubMed ID: 5715551
[No Abstract] [Full Text] [Related]
17. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation for Evans syndrome.
Oyama Y; Papadopoulos EB; Miranda M; Traynor AE; Burt RK
Bone Marrow Transplant; 2001 Nov; 28(9):903-5. PubMed ID: 11781654
[TBL] [Abstract][Full Text] [Related]
19. Post-hematopoietic stem cell transplantion immune-mediated cytopenias.
Tsirigotis PD; Resnick IB; Or R; Elad S; Zilberman I; Yoffe L; Levovic A; Miron S; Gesundheit B; Slavin S; Shapira MY
Immunotherapy; 2009 Jan; 1(1):39-47. PubMed ID: 20635972
[TBL] [Abstract][Full Text] [Related]
20. Dermatomyositis-like muscle pathology in patients with chronic graft-versus-host disease.
Allen JA; Greenberg SA; Amato AA
Muscle Nerve; 2009 Oct; 40(4):643-7. PubMed ID: 19670319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
